文献速递神经肌肉病

遗传性与获得性神经肌肉病患者的财务毒性及其决定因素:BIND研究

Financial Toxicity and Its Determinants in Individuals Living With Inherited and Acquired Neuromuscular Disorders: The BIND Study.
PubMed 文献 · Neurology · 2025-08-20

该研究在加拿大对1,426名神经肌肉病(NMD)患者或照护者开展全国横断面调查,采用经验证的COST量表评估财务毒性(FT)。平均COST得分为17.2(标准差10.4),70%的受访者COST得分低于26,提示中度或重度FT;照护者、少数族裔、低收入、低教育程度及无法工作者的FT更重。

要点

  • NMD患者中70%存在中度或重度财务毒性,平均COST得分17.2,低于其他慢性病包括癌症。
  • 照护者的COST得分显著差于成人NMD患者,是财务脆弱性的重点人群。
  • 少数族裔、低收入、低教育、无法工作、学生及提前退休者FT更重,自身免疫性肌病、脊髓性肌萎缩和肢带型肌营养不良患者FT亦更重。

核心结论

  • NMD患者中财务毒性高度流行,照护者及存在社会经济与临床脆弱性的人群尤为突出。
  • 改善NMD相关需求的财务支持与医保覆盖政策可能有助于减轻这一负担。

研究设计与样本

  • 加拿大全国横断面调查,对象为在加拿大肌肉萎缩症协会(MDC)登记的NMD患者或照护者,问卷为英文或法文,可在线或经MDC人员协助电话完成。
  • 共1,426名参与者完成调查,平均(标准差)年龄52.0(19.5)岁,52%为女性;采用经验证的COST-FACIT问卷测量财务毒性,并用多变量广义线性模型识别相关因素。

主要发现

  • 平均COST得分为17.2(10.4),显著低于其他慢性病包括癌症报告的得分。
  • 70%的受访者COST得分低于26,提示中度或重度财务毒性。
  • 调整其他因素后,照护者的COST得分显著差于成人NMD患者。
  • COST得分较低的相关因素包括少数族裔(RR 0.74;95%CI 0.64-0.87)、较低家庭收入(RR 0.59;95%CI 0.51-0.69)、较低教育程度(RR 0.91;95%CI 0.82-1.00)、无法工作(RR 0.74;95%CI 0.64-0.86)、学生(RR 0.54;95%CI 0.34-0.86)及提前退休(RR 0.86;95%CI 0.74-0.99)。

关键数值与推荐

  • COST得分低于26提示中度或重度财务毒性,本研究中70%的受访者低于该阈值。
  • 自身免疫性肌病(RR 0.82;95%CI 0.73-0.92)、脊髓性肌萎缩(RR 0.79;95%CI 0.66-0.96)和肢带型肌营养不良(RR 0.87;95%CI 0.77-0.99)患者FT更重。

临床怎么用

  • 在神经肌肉病随访中应常规关注患者及照护者的财务毒性,尤其对少数族裔、低收入、低教育、无法工作及特定亚型患者。
  • 可将COST等患者报告结局工具纳入评估,并联动社会支持与医保资源以减轻经济负担。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Individuals living with neuromuscular disease (NMD) often face substantial financial strain due to the chronic and progressive nature of these conditions. Despite growing awareness, the extent and determinants of financial toxicity (FT) in this population remain poorly understood. We assessed FT among individuals with NMD or their caregivers in Canada using a validated patient-reported outcome measure. METHODS: We conducted a national, cross-sectional survey of individuals with NMD or their caregivers registered with Muscular Dystrophy Canada (MDC). The survey, available in English and French, was completed online or by telephone with assistance from MDC personnel. FT was measured using the validated Comprehensive Score for Financial Toxicity (COST)-Functional Assessment of Chronic Illness Therapy questionnaire. Multivariable generalized linear models were used to identify factors associated with FT. RESULTS: A total of 1,426 participants (mean [SD] age, 52.0 [19.5] years; 52% female) completed the survey. Seventy-five percent reported household incomes below the national median, primarily because of reduced employment. The average COST score was 17.2 [10.4], significantly lower than scores reported in other chronic conditions, including cancer. Moreover, 70% of respondents had COST scores below 26, indicating moderate or severe FT. After adjusting for other factors, COST scores were significantly worse among caregivers than in adults with NMDs. Lower scores were also observed among individuals identified as racialized minority (rate ratio [RR] 0.74; 95% CI 0.64-0.87); those with lower household income (RR 0.59; 95% CI 0.51-0.69), those with lower education (RR 0.91; 95% CI 0.82-1.00), and those unable to work (RR 0.74; 95% CI 0.64-0.86); students (RR 0.54; 95% CI 0.34-0.86); or early retirees (RR 0.86, 95% CI 0.74-0.99). FT was also greater among those diagnosed with autoimmune myopathies (RR 0.82; 95% CI 0.73-0.92), spinal muscular atrophy (RR 0.79; 95% CI 0.66-0.96), and limb-girdle muscular dystrophy (RR 0.87; 95% CI 0.77-0.99). DISCUSSION: FT is highly prevalent among people living with NMDs, particularly caregivers and those with socioeconomic and clinical vulnerabilities. Policies to improve financial support and health care coverage for NMD-related needs could help alleviate this burden. Further research is required to understand the mechanisms contributing to FT within NMD subgroups.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Grant A, Smith IC, Lessard LER, et al. Financial Toxicity and Its Determinants in Individuals Living With Inherited and Acquired Neuromuscular Disorders: The BIND Study. Neurology. 2025. PMID: 40834345. doi:10.1212/WNL.0000000000213982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。